Form 4: Ultragenyx EVP and Chief Medical Officer Eric Crombez Reports Stock Sales

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., reported selling shares of common stock to cover tax obligations and participating in the employee stock purchase plan.

Summary

• Eric Crombez, an executive at Ultragenyx Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
• On April 21, 2025, Crombez sold 242 shares of common stock at $35.11 per share to cover tax withholdings related to vesting RSUs.
• On May 5, 2025, Crombez sold 520 shares of common stock at $39.24 per share.
• Crombez acquired 370 shares on April 30, 2025, under the company's employee stock purchase plan.
• Following these transactions, Crombez beneficially owns 71,530 shares of Ultragenyx common stock, which includes shares underlying previously reported RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions appear to be routine and related to tax obligations and participation in the employee stock purchase plan.

Positives

• Crombez's participation in the employee stock purchase plan indicates confidence in the company's future.

Industry Context

Form 4 filings are standard practice for company insiders and provide transparency into their transactions, allowing investors to gauge management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment if interpreted as a lack of confidence, but the employee stock purchase plan participation could offset this.

Key Dates

Keywords

Form 4, Ultragenyx, Crombez, Stock Sale, Beneficial Ownership, Employee Stock Purchase Plan, RSUs